

# Jonathan S Berek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6575046/publications.pdf>

Version: 2024-02-01

39  
papers

2,520  
citations

331670

21  
h-index

395702

33  
g-index

43  
all docs

43  
docs citations

43  
times ranked

3390  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 245-253.	6.3	5
2	Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. <i>Psycho-Oncology</i> , 2022, 31, 9-20.	2.3	29
3	Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update. <i>JCO Global Oncology</i> , 2022, 8, e2200027.	1.8	4
4	Association of illness mindsets with health-related quality of life in cancer survivors.. <i>Health Psychology</i> , 2022, 41, 389-395.	1.6	4
5	Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria. <i>JCO Global Oncology</i> , 2021, 7, 89-98.	1.8	6
6	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.	1.6	62
7	Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial. <i>JCO Global Oncology</i> , 2021, 7, 1418-1425.	1.8	6
8	FIGO staging for carcinoma of the vulva: 2021 revision. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 43-47.	2.3	42
9	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	2.3	145
10	Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes. <i>JCO Precision Oncology</i> , 2021, 5, 1853-1859.	3.0	2
11	Development of Therapeutic Vaccines for Ovarian Cancer. <i>Vaccines</i> , 2020, 8, 657.	4.4	15
12	Impact of mobile technologies on cervical cancer screening practices in Lagos, Nigeria (mHealth-Cervix): Protocol for a randomised controlled trial. <i>F1000Research</i> , 2020, 9, 322.	1.6	10
13	Revised FIGO staging for carcinoma of the cervix uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 145, 129-135.	2.3	612
14	Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e40.	2.2	31
15	ASCO 2019 meeting review. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e107.	2.2	2
16	Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. <i>Cell Reports</i> , 2018, 22, 1875-1888.	6.4	83
17	30 years of Current Opinion in Obstetrics and Gynecology: looking back and looking forward. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 99.	2.0	0
18	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 59-78.	2.3	205

#	ARTICLE	IF	CITATIONS
19	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2018, 19, 1117-1125.	10.7	95
20	Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. <i>Obstetrics and Gynecology</i> , 2017, 129, 202-202.	2.4	2
21	Immunotherapy in ovarian cancer. <i>Current Problems in Cancer</i> , 2017, 41, 48-63.	2.0	27
22	Reply to B.O. Anderson et al. <i>Journal of Global Oncology</i> , 2017, 3, 89-92.	0.5	0
23	Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 693-696.	2.5	19
24	Can Arts and Communication Programs Improve Physician Wellness and Mitigate Physician Suicide?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1820-1822.	1.6	17
25	Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 548-556.	0.6	46
26	An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 303-308.	0.6	13
27	The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. <i>Gynecological Surgery</i> , 2015, 12, 165-177.	0.9	158
28	Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. <i>Scientific Reports</i> , 2015, 4, 5810.	3.3	38
29	Immunotherapeutic approaches to ovarian cancer treatment. , 2015, 3, 7.		63
30	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S111-22.	2.3	70
31	Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. <i>International Journal of Oncology</i> , 2014, 45, 1691-1698.	3.3	82
32	Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1583-1589.	2.5	41
33	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S118-29.	2.3	194
34	Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy. <i>Obstetrics and Gynecology</i> , 2010, 116, 733-743.	2.4	89
35	Strategies and Goals: The Future of the International Gynecologic Cancer Society: IGCS Presidential Address. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1434-1439.	2.5	0
36	Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 418-425.	1.6	165

#	ARTICLE	IF	CITATIONS
37	Lymph Node-Positive Stage IIIC Ovarian Cancer: A Separate Entity?. International Journal of Gynecological Cancer, 2009, 19, S18-S20.	2.5	45
38	CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer. Journal of Immunotherapy, 2008, 31, 207-214.	2.4	44
39	Pharmacological activation of FOXO3 suppresses triple-negative breast cancer <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 0, 7, 42110-42125.	1.8	47